Track market-moving stories before they get noisy

Highlights of the second quarter include:

Net income increased 10% to $65.6 million, and net income margin increased to 19% from 18% last year.Adjusted EBITDA increased 11% to $167.0 million, and Adjusted EBITDA margin increased to 48% from 46% last year.Revenue increased 8% to $350.7 million.Net income per diluted share rose 15% to $0.78 from $0.68 one year ago, and non-GAAP net income per diluted share increased 15% to $1.24.Total HSA Assets grew 14% to $37.9 billion.Returned $108.1 million to shareholders through stock repurchases.
DRAPER, Utah, Aug. 27, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), the largest independent health savings account ("HSA") custodian by account volume and a leader in consumer-directed benefits ("CDBs"), today announced financial results for its second quarter ended July 31, 2026.

"HealthEquity delivered a record-setting second quarter, with record Adjusted EBITDA margin of 48%, record HSA accounts of 10.7 million and record HSA Assets of nearly $38 billion," said Scott Cutler, President and CEO of HealthEquity. "These results reflect strong execution across the business and the durability of our model as growth comes from more places, member relationships deepen and technology-enabled efficiency improves how we serve members and clients. This momentum gives us confidence to raise fiscal 2027 guidance and enter the second half focused on scaling efficiently and creating long-term value."

Second quarter financial results

Revenue for the second quarter ended July 31, 2026 was $350.7 million, an increase of 8% compared to $325.8 million for the second quarter ended July 31, 2025. Revenue this quarter included: service revenue of $124.4 million, custodial revenue of $175.9 million, and interchange revenue of $50.4 million.

Net income was $65.6 million, or $0.78 per diluted share, for the second quarter ended July 31, 2026, compared to $59.9 million, or $0.68 per diluted share, for the second quarter ended July 31, 2025. Net income margin was 19% for the second quarter ended July 31, 2026, compared to 18% for the second quarter ended July 31, 2025.

Non-GAAP net income was $103.8 million, or $1.24 per diluted share, for the second quarter ended July 31, 2026, compared to $94.6 million, or $1.08 per diluted share, for the second quarter ended July 31, 2025.

Adjusted EBITDA was $167.0 million for the second quarter ended July 31, 2026, an increase of 11% compared to the second quarter ended July 31, 2025. Adjusted EBITDA was 48% of revenue, compared to 46% for the second quarter ended July 31, 2025.

Account and asset metrics

New HSAs from sales were 202 thousand, an increase of 24% compared to the second quarter ended July 31, 2025. HSAs as of July 31, 2026 were 10.7 million, an increase of 8% year over year, including 0.9 million HSAs with investments, an increase of 20% year over year. Total Accounts as of July 31, 2026 were 17.8 million, including 7.0 million complementary CDBs.

Total HSA Assets as of July 31, 2026 were $37.9 billion, an increase of 14% year over year. Total HSA Assets included $17.4 billion of HSA cash and $20.6 billion of HSA investments. Client-held funds, which are deposits held on behalf of our Clients to facilitate administration of our CDBs, and from which we generate custodial revenue, were $0.9 billion as of July 31, 2026.

Stock repurchase program

The Company repurchased 1.2 million shares of its common stock for $108.1 million during the second quarter ended July 31, 2026. As of July 31, 2026, $948.4 million of common stock remained authorized for repurchase under the stock repurchase program.

Business outlook

For the fiscal year ending January 31, 2027, management is raising guidance and now expects revenues of $1.411 billion to $1.421 billion. Its outlook for net income is between $242 million and $248 million, resulting in net income of $2.88 to $2.96 per diluted share. Its outlook for non-GAAP net income, calculated using the method described below, is between $392 million and $398 million, resulting in non-GAAP net income per diluted share of $4.66 to $4.73 (based on an estimated 84 million diluted weighted-average shares outstanding). Management expects Adjusted EBITDA of $628 million to $636 million.

See “Non-GAAP financial information” below for definitions of our Adjusted EBITDA and non-GAAP net income. A reconciliation of the non-GAAP financial measures used throughout this release to the most comparable GAAP financial measures is included with the financial tables at the end of this release.

Conference call

HealthEquity management will host a conference call at 8:30 a.m. (Eastern Time) on Thursday, August 27, 2026 to discuss the fiscal 2027 second quarter financial results. The conference call will be accessible by dialing 1-833-630-1956, or 1-412-317-1837 for international callers, and referencing conference ID "HealthEquity." A live audio webcast of the call will be available on the investor relations section of our website at http://ir.healthequity.com.

Non-GAAP financial information

To supplement our financial information presented on a GAAP basis, we disclose non-GAAP financial measures, including Adjusted EBITDA, non-GAAP net income, and non-GAAP net income per diluted share.

Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.Non-GAAP net income is calculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.Non-GAAP net income per diluted share is calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding. Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP and should not be considered as a substitute for, or superior to, GAAP results. We believe that these non-GAAP financial measures provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. The Company cautions investors that non-GAAP financial information, by its nature, departs from GAAP; accordingly, its use can make it difficult to compare current results with results from other reporting periods and with the results of other companies. In addition, while amortization of acquired intangible assets is being excluded from non-GAAP financial measures, the revenue generated from those acquired intangible assets is not excluded. Whenever we use these non-GAAP financial measures, we provide a reconciliation of the applicable non-GAAP financial measure to the most closely applicable GAAP financial measure. Investors are encouraged to review the related GAAP financial measures and the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measure as detailed in the tables below.

About HealthEquity

HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for more than 17 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to save and improve lives by empowering healthcare consumers. For more information, visit www.healthequity.com.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “aims,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.

Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:

our ability to adequately place and safeguard our custodial assets, or the failure of any of our depository or insurance company partners;our ability to compete effectively in a rapidly evolving healthcare and benefits administration industry;our dependence on the continued availability and benefits of tax-advantaged HSAs and other CDBs;the impact of fraudulent account activity involving our member accounts or our third-party service providers on our reputation and financial results;our ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets;the significant competition we face and may face in the future, including from those with greater resources than us;our reliance on the availability and performance of our technology and communications systems;potential future cybersecurity breaches of our technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage and loss of business;the current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations;our ability to comply with current and future privacy, healthcare, tax, ERISA, investment adviser and other laws applicable to our business;our reliance on partners and third-party vendors for distribution and important services;our ability to develop and implement updated features for our technology platforms and communications systems; andour reliance on our management team and key team members. For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the fiscal year ended January 31, 2026 and subsequent periodic and current reports. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Relations Contact
Richard Putnam
801-727-1000
[email protected]

HealthEquity, Inc. and subsidiaries
Condensed consolidated balance sheets
       (in thousands, except par value)July 31, 2026
  January 31, 2026
  (unaudited)
   Assets   Current assets   Cash and cash equivalents$                       256,003  $                       318,927 Accounts receivable, net of allowance for doubtful accounts of $1,067 and $924 as of July 31,
2026 and January 31, 2026, respectively                         122,193                           123,696 Prepaid expenses and other current assets                           82,008                             69,658 Total current assets                         460,204                           512,281 Property and equipment, net                             4,823                               3,177 Operating lease right-of-use assets                           32,874                             36,310 Intangible assets, net                      1,047,797                        1,097,172 Goodwill                       1,648,145                         1,648,145 Other assets                           77,520                             83,247 Total assets$                    3,271,363  $                    3,380,332 Liabilities and stockholders’ equity   Current liabilities   Accounts payable$                          8,592  $                        12,159 Accrued compensation                           37,913                             60,392 Accrued liabilities                           97,300                             74,388 Operating lease liabilities                             9,970                               9,911 Total current liabilities                          153,775                            156,850 Long-term liabilities   Long-term debt, net of issuance costs                          931,062                            957,379 Operating lease liabilities, non-current                           29,984                             34,190 Other long-term liabilities                           73,999                             31,007 Deferred tax liability                           92,433                             93,710 Total long-term liabilities                      1,127,478                        1,116,286 Total liabilities                      1,281,253                        1,273,136 Commitments and contingencies   Stockholders’ equity   Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and
outstanding as of July 31, 2026 and January 31, 2026, respectively                                   —                                     — Common stock, $0.0001 par value, 900,000 shares authorized, 82,909 and 85,007 shares
issued and outstanding as of July 31, 2026 and January 31, 2026, respectively                                    8                                      8 Additional paid-in capital                       1,896,571                         1,916,989 Accumulated earnings                         162,583                           195,906 Accumulated other comprehensive loss                          (69,052)                             (5,707)Total stockholders’ equity                      1,990,110                        2,107,196 Total liabilities and stockholders’ equity$                    3,271,363  $                    3,380,332  HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of operations (unaudited)    Three months ended July 31,
  Six months ended July 31,
 (in thousands, except per share data) 2026   2025   2026   2025 Revenue       Service revenue$              124,444  $              117,873  $              247,376  $              237,657 Custodial revenue                 175,936                   159,876                   350,270                   316,331 Interchange revenue                  50,352                    48,086                   107,727                   102,691 Total revenue                 350,732                   325,835                   705,373                   656,679 Cost of revenue       Service costs                  73,170                    75,156                   151,496                   163,161 Custodial costs                  12,083                    11,137                    23,738                    21,884 Interchange costs                    7,525                      6,947                    15,873                    14,728 Total cost of revenue                  92,778                    93,240                   191,107                   199,773 Gross profit                 257,954                   232,595                   514,266                   456,906 Operating expenses       Sales and marketing                  23,215                    19,922                    50,048                    45,906 Technology and development                  73,923                    64,804                   141,690                   126,240 General and administrative                  34,869                    29,990                    66,000                    55,526 Amortization of acquired intangible assets                  26,286                    27,001                    52,801                    54,003 Merger integration                       971                      1,266                      2,084                      2,541 Total operating expenses                 159,264                   142,983                   312,623                   284,216 Income from operations                  98,690                    89,612                   201,643                   172,690 Other expense       Interest expense                 (12,605)                  (14,955)                  (25,193)                  (29,813)Other income, net                    1,780                      3,391                      3,828                      6,124 Total other expense                 (10,825)                  (11,564)                  (21,365)                  (23,689)Income before income taxes                  87,865                    78,048                   180,278                   149,001 Income tax provision                  22,221                    18,194                    45,216                    35,232 Net income$               65,644  $               59,854  $              135,062  $              113,769 Net income per share:       Basic$                   0.79  $                   0.69  $                   1.61  $                   1.31 Diluted$                   0.78  $                   0.68  $                   1.60  $                   1.29 Weighted-average number of shares used in computing net income per share:       Basic                  83,374                    86,550                    83,885                    86,601 Diluted                  84,014                    87,746                    84,578                    88,153  HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of comprehensive income (unaudited)    Three months ended July 31, Six months ended July 31,(in thousands) 2026   2025  2026   2025Net income$               65,644  $               59,854 $              135,062  $              113,769Other comprehensive income (loss)       Cash flow hedges       Net unrealized gains (losses)                 (37,322)                        203                  (63,219)                        203Reclassification of net (gains) losses included in net income                         22                            —                       (126)                           —Net change, net of income tax benefit (expense) of $12,135, $(70), $20,598, and $(70), respectively                 (37,300)                        203                  (63,345)                        203Total other comprehensive income (loss)                 (37,300)                        203                  (63,345)                        203Comprehensive income$               28,344  $               60,057 $               71,717  $              113,972 HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited)   Six months ended July 31,
 (in thousands) 2026   2025 Cash flows from operating activities:   Net income$                       135,062  $                       113,769 Adjustments to reconcile net income to net cash provided by operating activities:   Depreciation and amortization                           80,169                             77,195 Stock-based compensation                           41,616                             33,404 Amortization of debt discount and issuance costs                                558                                  533 Amortization of gains on derivatives                               (168)                                    — Deferred taxes                           19,321                             30,711 Changes in operating assets and liabilities:   Accounts receivable, net                             1,503                               6,842 Prepaid expenses and other current and non-current assets                          (12,581)                           (20,650)Operating lease right-of-use assets                             3,436                               3,339 Accrued compensation                          (21,095)                           (35,032)Accounts payable, accrued liabilities, and other current liabilities                          (13,595)                             (3,785)Operating lease liabilities, non-current                            (4,206)                             (3,951)Other long-term liabilities                             3,665                              (1,771)Net cash provided by operating activities                          233,685                            200,604 Cash flows from investing activities:   Capitalized software development costs                          (30,720)                           (26,464)Purchases of property and equipment                            (1,340)                                (859)Settlement of derivatives, net                            (7,759)                                    — Net cash used in investing activities                          (39,819)                           (27,323)Cash flows from financing activities:   Repurchases of common stock                        (231,054)                         (125,810)Principal payments on long-term debt                          (26,875)                           (50,000)Settlement of client-held funds obligation, net                                480                                  596 Proceeds from exercise of common stock options                                659                             10,446 Net cash used in financing activities                        (256,790)                         (164,768)Increase (decrease) in cash and cash equivalents                          (62,924)                              8,513 Beginning cash and cash equivalents                          318,927                            295,948 Ending cash and cash equivalents$                       256,003  $                       304,461  HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited) (continued)  Six months ended July 31,(in thousands) 2026  2025Supplemental cash flow data:   Interest expense paid in cash$                        23,350 $                        28,362Income tax payments, net                           35,586                              6,507Supplemental disclosures of non-cash investing and financing activities:   Capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation                             3,434                              3,380Purchases of property and equipment included in accounts payable or accrued liabilities                             1,294                                 155Repurchases of common stock included in accrued liabilities                             3,255                              1,246Exercise of common stock options receivable                                  57                                    — Stock-based compensation expense (unaudited)Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive income is as follows:

 Three months ended July 31, Six months ended July 31,(in thousands) 2026  2025  2026  2025Cost of revenue$                 2,713 $                 3,114 $                 5,500 $                 6,501Sales and marketing                    3,229                     1,529                     7,753                     6,399Technology and development                    6,178                     5,732                   10,131                   11,652General and administrative                  10,090                     8,693                   18,232                     8,852Total stock-based compensation expense$               22,210 $               19,068 $               41,616 $               33,404 Total Accounts (unaudited)       (in thousands, except percentages)July 31, 2026 July 31, 2025 % Change January 31, 2026HSAs                 10,739                    9,989 8 %
                  10,570New HSAs from sales - Quarter-to-date                      202                       163 24 %
                       553New HSAs from sales - Year-to-date                      374                       312 20 %
                    1,040New HSAs from acquisitions - Year-to-date                         —                          — *                          —HSAs with investments                      939                       782 20 %
                       832CDBs                   7,016                    7,153 (2)%                    7,221Total Accounts                 17,755                  17,142 4 %
                  17,791Average Total Accounts - Quarter-to-date                 17,710                  17,044 4 %
                  17,462Average Total Accounts - Year-to-date                 17,772                  17,083 4 %
                  17,220 *     Not meaningful

HSA Assets (unaudited)       (in millions, except percentages)July 31, 2026 July 31, 2025 % Change January 31, 2026HSA cash$               17,369 $               17,035 2%
 $               17,982HSA investments                  20,552                   16,102 28%
                   18,482Total HSA Assets                  37,921                   33,137 14%
                   36,464Average daily HSA cash - Quarter-to-date                  17,388                   17,017 2%
                   17,090Average daily HSA cash - Year-to-date                  17,547                   17,149 2%
                   17,082 HSA cash maturity scheduleThe following table summarizes the amount of HSA cash held by our depository partners and insurance company partners that is expected to reprice by fiscal year and the respective average annualized yield currently earned on that HSA cash as of July 31, 2026:

Year ending January 31, (in billions, except percentages)HSA cash expected to reprice Average annualized yieldRemainder of 2027$                              2.3 1.5%
2028                                 2.5 4.0%
2029                                 1.8 3.8%
2030                                 2.3 4.4%
Thereafter                                 7.8 4.4%
Total (1)$                            16.7 3.9%
(1)  Excludes $0.7 billion of HSA cash held in floating-rate contracts as of July 31, 2026.

Client-held funds (unaudited)       (in millions, except percentages)July 31, 2026 July 31, 2025 % Change January 31, 2026Client-held funds$                    931 $                    818 14 %
 $                 1,090Average daily Client-held funds - Quarter-to-date                       936                        884 6 %
                        879Average daily Client-held funds - Year-to-date                       986                        893 10 %
                        864 Reconciliation of net income to Adjusted EBITDA (unaudited)    Three months ended July 31,
  Six months ended July 31,
 (in thousands) 2026   2025   2026   2025 Net income$               65,644  $               59,854  $              135,062  $              113,769 Interest income                   (1,760)                    (3,364)                    (3,647)                    (6,097)Interest expense                  12,605                    14,955                    25,193                    29,813 Income tax provision                  22,221                    18,194                    45,216                    35,232 Depreciation and amortization                  15,669                    11,453                    27,368                    23,192 Amortization of acquired intangible assets                  26,286                    27,001                    52,801                    54,003 Stock-based compensation expense                  22,210                    19,068                    41,616                    33,404 Merger integration expenses                       971                      1,266                      2,084                      2,541 Amortization of incremental costs to obtain a contract                    2,139                      1,951                      4,255                      3,877 Costs associated with unused office space                    1,016                         723                      1,702                      1,575 Other                        (20)                         (27)                       (181)                         (27)Adjusted EBITDA$              166,981  $              151,074  $              331,469  $              291,282  Net income and Adjusted EBITDA as a percentage of revenue (unaudited) Three months ended July 31,     Six months ended July 31,    (in thousands, except
percentages) 2026   2025  $ Change % Change  2026   2025  $ Change % ChangeNet income$      65,644  $      59,854  $     5,790 10 % $    135,062  $    113,769  $   21,293 19 %As a percentage of revenue 19 %  18%      19 %  17 %    Adjusted EBITDA$    166,981  $    151,074  $   15,907 11  % $    331,469  $    291,282  $   40,187 14 %As a percentage of revenue 48 %  46%      47 %  44 %     Reconciliation of net income outlook to Adjusted EBITDA
(unaudited)  Outlook for the year ending(in millions)January 31, 2027Net income$242 - 248Interest income(7)
Interest expense50
Income tax provision81 - 83Depreciation and amortization54
Amortization of acquired intangible assets104
Stock-based compensation expense87
Merger integration expenses5
Amortization of incremental costs to obtain a contract9
Costs associated with unused office space3
Adjusted EBITDA$628 - 636 Note: Values presented may not calculate due to rounding.

Reconciliation of net income to non-GAAP net income (unaudited)

    Three months ended July 31, Six months ended July 31,(in thousands, except per share data) 2026  2025  2026  2025Net income$               65,644 $               59,854 $              135,062 $              113,769Income tax provision                  22,221                   18,194                   45,216                   35,232Income before income taxes - GAAP                  87,865                   78,048                  180,278                  149,001Non-GAAP adjustments:       Amortization of acquired intangible assets                  26,286                   27,001                   52,801                   54,003Stock-based compensation expense                  22,210                   19,068                   41,616                   33,404Merger integration expenses                       971                     1,266                     2,084                     2,541Costs associated with unused office space                    1,016                        723                     1,702                     1,575Total adjustments to income before income taxes - GAAP                  50,483                   48,058                   98,203                   91,523Income before income taxes - Non-GAAP                 138,348                  126,106                  278,481                  240,524Income tax provision - Non-GAAP (1)                  34,586                   31,526                   69,620                   60,130Non-GAAP net income                 103,762                   94,580                  208,861                  180,394        Diluted weighted-average shares                  84,014                   87,746                   84,578                   88,153GAAP net income per diluted share$                   0.78 $                   0.68 $                   1.60 $                   1.29Non-GAAP net income per diluted share$                   1.24 $                   1.08 $                   2.47 $                   2.05 (1)The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations. Reconciliation of net income outlook to non-GAAP net income outlook (unaudited)

  Outlook for the year ending(in millions, except per share data)January 31, 2027Net income$242 - 248Income tax provision81 - 83Income before income taxes - GAAP323 - 331Non-GAAP adjustments: Amortization of acquired intangible assets104Stock-based compensation expense87Merger integration expenses5Costs associated with unused office space3Total adjustments to income before income taxes - GAAP199Income before income taxes - Non-GAAP522 - 530Income tax provision - Non-GAAP (1)131 - 133Non-GAAP net income$392 - 398  Diluted weighted-average shares84GAAP net income per diluted share$2.88 - 2.96Non-GAAP net income per diluted share$4.66 - 4.73 Note: Values presented may not calculate due to rounding.

(1) The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations. Certain termsTermDefinitionHSAHealth Savings Account, which is a financial account through which consumers spend and save long-term for healthcare on a tax-advantaged basis.CDBConsumer-directed benefits offered by employers, including flexible spending and health reimbursement arrangements (“FSAs” and “HRAs”), Consolidated Omnibus Budget Reconciliation Act (“COBRA”) administration, commuter and other benefits.HSA memberConsumers with HSAs that we serve.Total HSA AssetsHSA members’ custodial cash assets held by our federally insured depository partners and our insurance company partners. Total HSA Assets also includes HSA members' investments held by our custodial investment fund partner.ClientOur employer clients.Total AccountsThe sum of HSAs and CDBs on our platforms.Client-held fundsDeposits held on behalf of our Clients to facilitate administration of our CDBs.Network PartnerOur health plan partners, benefits administrators, and retirement plan recordkeepers.Adjusted EBITDAEarnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.Non-GAAP net incomeCalculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.Non-GAAP net income per diluted shareCalculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.

Canada Pension Plan Investment Board purchased a new stake in HealthEquity, Inc. (NASDAQ:HQY – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 135,600 shares of the company’s stock, valued at approximately $12,247,000. Canada Pension Plan Investment Board owned 0.16% of HealthEquity as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Acumen Wealth Advisors LLC acquired a new stake in shares of HealthEquity during the 4th quarter worth approximately $27,000. Caitong International Asset Management Co. Ltd lifted its position in shares of HealthEquity by 1,723.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $28,000 after acquiring an additional 293 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in shares of HealthEquity during the 4th quarter valued at $28,000. Leonteq Securities AG boosted its stake in HealthEquity by 159.9% during the first quarter. Leonteq Securities AG now owns 382 shares of the company’s stock worth $32,000 after acquiring an additional 235 shares in the last quarter. Finally, Axiom Investment Management LLC bought a new position in HealthEquity during the first quarter worth $33,000. 99.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In HQY has been the subject of several research analyst reports. Wells Fargo & Company set a $111.00 price target on shares of HealthEquity in a research note on Monday, June 1st. Citigroup reissued a “market outperform” rating on shares of HealthEquity in a research report on Friday. Weiss Ratings upgraded HealthEquity from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, June 5th. Royal Bank Of Canada raised their target price on HealthEquity from $100.00 to $108.00 and gave the company an “outperform” rating in a research note on Wednesday, June 3rd. Finally, Telsey Advisory Group set a $111.00 target price on HealthEquity in a research report on Friday. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $110.93.

Check Out Our Latest Analysis on HQY More HealthEquity News Here are the key news stories impacting HealthEquity this week:

Positive Sentiment: HealthEquity exceeded expectations with adjusted earnings of $1.24 per share versus the $1.19 consensus, while revenue reached $350.7 million, slightly above estimates. Revenue increased 95.5% year over year. HealthEquity Q2 Earnings and Revenues Top Estimates Positive Sentiment: Profitability improved, with net income rising 10% to $65.6 million and net margin expanding to 19% from 18%. Adjusted EBITDA grew 11% to $167 million, while its margin increased to 48% from 46%. HealthEquity Second-Quarter Financial Results Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $4.66–$4.73, above the $4.56 analyst consensus. Record HSA assets of $37.9 billion provide additional support for the company’s long-term growth outlook. HealthEquity Raises Fiscal 2027 Guidance Positive Sentiment: BTIG Research reaffirmed its “buy” rating and raised its price target to $115. Another analysis indicated that HQY could be approximately 19% undervalued after the guidance increase, reinforcing the bullish interpretation of the earnings update. BTIG Research Rating HealthEquity Could Be Undervalued Neutral Sentiment: Fiscal 2027 revenue guidance of approximately $1.4 billion was broadly in line with expectations, so the guidance improvement was driven mainly by stronger anticipated earnings and margins. Negative Sentiment: Director Adrian T. Dillon sold 7,632 shares valued at approximately $798,000, reducing his position by 10.9%. The sale was executed under a pre-arranged Rule 10b5-1 plan, which reduces its negative signaling value but could still attract investor attention. HealthEquity Director Stock Sale Negative Sentiment: HQY trades at a premium valuation of roughly 35 times earnings. After the recent advance toward its 52-week high, some investors may lock in gains, potentially tempering the stock’s reaction to otherwise favorable fundamentals. Insider Transactions at HealthEquity In other news, Director Adrian T. Dillon sold 7,632 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $104.61, for a total value of $798,383.52. Following the completion of the sale, the director directly owned 62,395 shares of the company’s stock, valued at $6,527,140.95. This represents a 10.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Henry Fiore sold 2,470 shares of the stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $95.00, for a total value of $234,650.00. Following the completion of the sale, the executive vice president directly owned 56,643 shares of the company’s stock, valued at approximately $5,381,085. This trade represents a 4.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 12,456 shares of company stock valued at $1,256,664 in the last quarter. Company insiders own 1.60% of the company’s stock.

HealthEquity Stock Performance NASDAQ HQY opened at $96.37 on Friday. The company has a fifty day simple moving average of $98.16 and a 200 day simple moving average of $87.87. HealthEquity, Inc. has a 12-month low of $72.76 and a 12-month high of $107.62. The company has a current ratio of 2.99, a quick ratio of 3.44 and a debt-to-equity ratio of 0.47. The company has a market cap of $8.06 billion, a P/E ratio of 34.79, a PEG ratio of 1.62 and a beta of 0.21.

HealthEquity (NASDAQ:HQY – Get Free Report) last posted its earnings results on Thursday, August 27th. The company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.19 by $0.05. HealthEquity had a net margin of 17.36% and a return on equity of 15.33%. The company had revenue of $350.73 million during the quarter, compared to the consensus estimate of $349.22 million. HealthEquity’s revenue was up 95.5% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. Sell-side analysts predict that HealthEquity, Inc. will post 3.92 earnings per share for the current fiscal year.

HealthEquity Company Profile (Free Report)

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.

Featured Stories Five stocks we like better than HealthEquity From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash Venture Into High-Volatility Corners of the Market With These 3 ETFs 3 Retail Stocks to Watch After a Big Consumer Earnings Week Want to see what other hedge funds are holding HQY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HealthEquity, Inc. (NASDAQ:HQY – Free Report).

Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.